Ultra-high-sensitivity next-generation sequencing–based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: results from the ALFA-1200 cohort

1

Measurable residual disease (MRD) is a key biomarker for post-remission risk stratification in acute myeloid leukemia (AML).
2

Ultra-high-sensitivity next-generation sequencing (UHS-NGS) allows tracking of multiple leukemia-associated mutations at low frequencies for MRD assessment.
3

Older AML patients often have distinct molecular features, necessitating dedicated clinical data for UHS-NGS MRD interpretation.
4

In the ALFA-1200 study, MRD positivity was linked to significantly higher relapse rates and lower survival outcomes in older AML patients.
5

The study suggests a quantitative approach to interpreting mutations in older AML patients, particularly regarding myelodysplasia-related genes.

Blood Cancer Journal

by Augustin Boudry, Laurène Fenwarth, Raphaël Itzykson, Thorsten Braun, Lionel Adès, Élise Fournier, Céline Berthon, Delphine Lebon, Stéphane De Botton, Régis Peffault de Latour, Cécile Pautas, Hervé Dombret, Emmanuel Raffoux, Claude Gardin, Karine Celli-Lebras, Claude Preudhomme, Nicolas Duployez
May 28, 2026

1